Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Senior Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • ATOR-4066
      • ALG.APV-527
    • Scientific publications
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Corporate deck
    • Capital raisings
      • Preferential Rights Issue Q1 2025
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
Key downloads
Alligator Bioscience AB reports financial results for Q2 2025 and provides a business updateBulletin from the annual general meeting in Alligator Bioscience AB on 7 May 2025Alligator Bioscience AB reports financial results for Q1 2025 and provides a business updateAlligator Bioscience publishes Annual Report for 2024Bulletin from the extraordinary general meeting in Alligator Bioscience AB
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRRegulatoryReport
View as grid View as list
2021-10-21

Alligator Bioscience AB: Correction regarding MAR marking

The press release as of October 21, 2021 regarding the Interim report January – September 2021 incorrectly contained a so-called MAR marking ...
Continue reading
2021-10-21
Regulatory

Alligator Bioscience AB: Interim report January–September 2021

First Patient Dosed in Optimize-1 Phase II “We continued to make great strides in the third quarter of 2021. The first patient was dosed in ...
Continue reading
2021-10-21

Alligator Announces First Patient Dosed in Phase II Clinical Trial with Shanghai Henlius Biotech, Inc. & AbClon, Inc.

Lund, Sweden, October 20, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced that the Company was notified that t ...
Continue reading
2021-10-15

Invitation to the Presentation of Alligator Bioscience´s Interim Report January – September 2021 on October 21, 2021

LUND (Sweden) – Alligator Bioscience will host a conference call (in English) investors, analysts and media on Thursday, October 21st, 2021, ...
Continue reading
2021-10-07

Notice of extraordinary general meeting in Alligator Bioscience AB

The shareholders of Alligator Bioscience AB, Reg. No. 556597-8201 (“Alligator”), are invited to the extraordinary general meeting to be held ...
Continue reading
2021-10-07
Regulatory

Alligator carries out a 100 percent secured rights issue of approximately SEK 257 million

The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or "the Company") has today, subject to approval by th ...
Continue reading
2021-09-30

Alligator Bioscience Announces First Patient Dosed in OPTIMIZE-1 Phase II Clinical Trial Evaluating Mitazalimab in Combination with mFOLFIRINOX for the Treatment of Pancreatic Cancer

Lund, Sweden, September 30, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that it has dosed the first patient in it ...
Continue reading
2021-09-22

Alligator to Participate in Upcoming Investor Conferences

Lund, Sweden, September 23, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that Søren Bregenholt, Chief Execu ...
Continue reading
2021-09-02
Regulatory

Alligator is exploring financing alternatives to support phase II studies for Mitazalimab, phase II preparations for ATOR-1017 as well as the development of other pipeline

Lund, Sweden, September 2, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announces that the Company, in order to enabl ...
Continue reading

Posts navigation

Older posts
Newer posts
  1. Startpage
  2. News
About Alligator

Alligator, a clinical-stage biotechnology company, develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
  • Glossary
Contact us

Headquarter
Alligator Bioscience AB
Medicon Village
Scheeletorget 1
SE-223 81 Lund Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2024 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all